Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health ProgramsGlobeNewsWire • 09/01/20
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1 Phase 1 Human Clinical Study for the Prevention of PreGlobeNewsWire • 08/19/20
Daré Bioscience, Inc.'s (DARE) CEO Sabrina Martucci Johnson on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/13/20
Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual ConferenceGlobeNewsWire • 08/06/20
Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020GlobeNewsWire • 08/05/20
Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal SymptomsGlobeNewsWire • 07/27/20
Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of ReproductionGlobeNewsWire • 06/24/20
Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial VaginosisGlobeNewsWire • 06/17/20
Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible ContraceptiveGlobeNewsWire • 06/15/20
Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20
Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company UpdateGlobeNewsWire • 05/14/20
Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®GlobeNewsWire • 04/01/20
Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/30/20
Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial VaginosisGlobeNewsWire • 03/10/20
Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal DisorderGlobeNewsWire • 03/09/20
Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of BiopharmaSeeking Alpha • 12/23/19
Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical StudyGlobeNewsWire • 12/18/19
Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal DisorderGlobeNewsWire • 12/11/19
Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery PlatformGlobeNewsWire • 11/21/19
Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/15/19
Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery PlatformGlobeNewsWire • 11/11/19
Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America ConferenceGlobeNewsWire • 10/28/19